Analysts predict that Pluristem Therapeutics Inc. (NASDAQ:PSTI) will post ($0.08) earnings per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Pluristem Therapeutics’ earnings. Pluristem Therapeutics also posted earnings per share of ($0.08) during the same quarter last year. The firm is expected to announce its next earnings results on Wednesday, February 14th.

According to Zacks, analysts expect that Pluristem Therapeutics will report full year earnings of ($0.34) per share for the current financial year, with EPS estimates ranging from ($0.34) to ($0.33). For the next fiscal year, analysts expect that the firm will report earnings of ($0.31) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Pluristem Therapeutics.

Pluristem Therapeutics (NASDAQ:PSTI) last posted its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08).

A number of equities research analysts recently weighed in on PSTI shares. HC Wainwright set a $4.00 price objective on shares of Pluristem Therapeutics and gave the company a “buy” rating in a research note on Tuesday, January 16th. Maxim Group set a $2.00 price objective on shares of Pluristem Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 19th. ValuEngine cut shares of Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 20th. Finally, Zacks Investment Research upgraded shares of Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Several hedge funds and other institutional investors have recently modified their holdings of PSTI. Psagot Investment House Ltd. raised its stake in shares of Pluristem Therapeutics by 1,705.2% during the third quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 122,347 shares in the last quarter. Heritage Investors Management Corp bought a new stake in shares of Pluristem Therapeutics during the third quarter valued at about $113,000. Finally, Jane Street Group LLC raised its stake in shares of Pluristem Therapeutics by 15.0% during the third quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock valued at $402,000 after purchasing an additional 34,742 shares in the last quarter. Institutional investors and hedge funds own 4.34% of the company’s stock.

Shares of Pluristem Therapeutics (NASDAQ:PSTI) opened at $1.35 on Friday. Pluristem Therapeutics has a one year low of $1.06 and a one year high of $2.12. The firm has a market cap of $149.27, a PE ratio of -4.35 and a beta of 0.19.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Pluristem Therapeutics Inc. (PSTI) Will Post Earnings of -$0.08 Per Share” was first published by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2018/02/08/zacks-analysts-expect-pluristem-therapeutics-inc-psti-will-post-earnings-of-0-08-per-share.html.

About Pluristem Therapeutics

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.